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ABSTRACT
Polymorphism in the human leukocyte antigen (HLA) loci ensures that the CD8 T cell response to viruses is directed against a
diverse range of antigenic epitopes, thereby minimizing the impact of virus escape mutation across the population. The BZLF1
antigen of Epstein-Barr virus is an immunodominant target for CD8 T cells, but the response has been characterized only in
the context of a limited number of HLAmolecules due to incomplete epitope mapping. We have now greatly expanded the num-
ber of defined CD8 T cell epitopes from BZLF1, allowing the response to be evaluated in a much larger proportion of the popu-
lation. Some regions of the antigen fail to be recognized by CD8 T cells, while others include clusters of overlapping epitopes
presented by different HLAmolecules. These highly immunogenic regions of BZLF1 include polymorphic sequences, such that
up to four overlapping epitopes are impacted by a single amino acid variation common in different regions of the world. This
focusing of the immune response to limited regions of the viral protein could be due to sequence similarity to human proteins
creating “immune blind spots” through self-tolerance. This study significantly enhances the understanding of the immune re-
sponse to BZLF1, and the precisely mapped T cell epitopes may be directly exploited in vaccine development and adoptive im-
munotherapy.
IMPORTANCE
Epstein-Barr virus (EBV) is an important human pathogen, associated with several malignancies, including nasopharyngeal car-
cinoma and Hodgkin lymphoma. T lymphocytes are critical for virus control, and clinical trials aimed at manipulating this arm
of the immune system have demonstrated efficacy in treating these EBV-associated diseases. These trials have utilized informa-
tion on the precise location of viral epitopes for T cell recognition, for either measuring or enhancing responses. In this study, we
have characterized the T cell response to the highly immunogenic BZLF1 antigen of EBV by greatly expanding the number of
defined T cell epitopes. An unusual clustering of epitopes was identified, highlighting a small region of BZLF1 that is targeted by
the immune response of a high proportion of the world’s population. This focusing of the immune response could be utilized in
developing vaccines/therapies with wide coverage, or it could potentially be exploited by the virus to escape the immune re-
sponse.
Epstein-Barr virus (EBV), a lymphotropic gamma-1 herpesvi-rus, is widespread in all human populations, infecting around
95% of the adult population worldwide. Transmission of this life-
long persistent virus is via the oral route. After close contact, viral
particles present in the saliva of infected individuals enter the oral
cavity of the naive individual, and the virus is amplified by repli-
cative (lytic) infection in permissive cells in the oropharynx. This
lytic infection results in vast amounts of virus shedding into the
throat. Simultaneously, infection of mucosal B cells occurs, and
the virus initiates latent, persistent infection of the B cell pool
(1–3). In developing countries, EBV is associated with an asymp-
tomatic infection, usually occurring in infancy or early childhood.
In developed countries, however, acute infection is often delayed un-
til adolescence or early adulthood and, in around 25% of cases, can
result in the self-limiting lymphoproliferative disorder infectious
mononucleosis (IM). IM was etiologically linked to EBV in 1968 by
Henle et al. (4). Symptoms associated with IM range from fever and
sore throat to lymphadenopathy and splenomegaly (3–5).
Around 80 EBV proteins are expressed during lytic viral repli-
cation, which involves the sequential expression of immediate
early, early, and late proteins. Lytic cycle activation is initiated by
the expression of two immediate early proteins, BZLF1 (Zta) and
BRLF1 (Rta). Cox et al. noted that Rta and Zta appeared to regu-
late gene expression at the level of transcription and that these
transactivators work in concert to facilitate reactivation (6). Our
protein of interest, BZLF1, or ZEBRA (Z EBV replication activa-
tor), is a member of the basic leucine zipper family which binds to
the AP1-like Z response elements in EBV early promoters (7) and
exhibits sequence similarity to c-Fos (8). In addition to the trans-
activation domain (amino acids [aa] 1 to 166), BZLF1 contains a
basic DNA recognition domain (aa 178 to 194) and a coiled-coil
dimerization domain (aa 198 to 225) (9, 10).
The adaptive immune response is vital in controlling EBV-
infected B-cell proliferation and is of immense importance during
persistent infection (1). CD8 T cells recognize peptides derived
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fromviral proteins associatedwithmajor histocompatibility com-
plex (MHC) molecules. Results from Pudney et al. suggest a fo-
cusing of CD8 T cell responses toward epitopes from immediate
early and early proteins and a hierarchy of immunodominance
among the EBV lytic cycle antigens (11). The lytic protein BZLF1
includes a number of defined CD8 T cell epitopes presented
by HLA-B and -C alleles. The most widely studied is the HLA-
B8-restricted RAKFKQLL epitope. Tan et al. demonstrated
that up to 5.5% of CD8 T cells in the peripheral circulation of
healthy virus carriers are specific for this epitope (12). Other
CD8 BZLF1 epitopes include the highly immunogenic 13-mer
LPEPLPQGQLTAY, presented by HLA-B*3508, which overlaps
with the HLA-B*3501-restricted EPLPQGQLTAY epitope (13).
Recently, we defined two novel overlapping epitopes fromBZLF1:
an HLA-B*1801-restricted octamer, SELEIKRY, which is encom-
passed by the HLA-B*4403-restricted EECDSELEIKRY dodeca-
mer (14).
In the present study, we further investigated the CD8 T cell
response to the BZLF1 protein, identifying 11 novel epitopes,
many presented by common HLA alleles. Interestingly, these
epitopes appear to be clustered within certain domains of the pro-
tein, with many overlapping sequences.
MATERIALS AND METHODS
Generation of T cell lines. PBMCs were isolated by Ficoll-Hypaque cen-
trifugation into RPMI 1640 medium supplemented with 10% fetal calf
serum (FCS) (R10). Blood donors were healthy, EBV-seropositive indi-
viduals who had given written informed consent. Approval for this re-
searchwas obtained from theQIMRBerghoferMedical Research Institute
Human Ethics Committee (Brisbane, Australia). EBV-specific T cell cul-
tures were raised by culturing peripheral blood mononuclear cells
(PBMCs) (2 106/2-ml well) with irradiated autologous lymphoblastoid
cell lines (LCLs) transformed with the B95-8 strain of EBV (2 105/2 ml
well). Cultures were supplemented with recombinant interleukin 2
(rIL-2) (120 IU/ml) from day 3 and analyzed on day 18.
Peptides. Forty-six overlapping peptides (20-mers overlapping by 15
aa) covering the entire length of BZLF1 were designed based on the se-
quence of the B95.8 strain of EBV. Synthetic peptides were purchased
from either New England Peptides (Gardner, MA) or GL Biochem
(Shanghai, China) and dissolved in dimethyl sulfoxide (DMSO).
ELISpot assays. Gamma interferon (IFN-) enzyme-linked immu-
nosorbent spot (ELISpot) assays were performed using cytokine capture
and detection reagents according to the manufacturer’s instructions
(ELISpotPRO for human IFN-; Mabtech, Stockholm, Sweden). Briefly,
96-well nitrocellulose plates precoated with anti-IFN-monoclonal anti-
body (MAb) were seeded with approximately 5 104 EBV-specific T cells
and peptide at various concentrations. After incubation for 16 h at 37°C in
5%CO2, the cells were discarded and captured IFN-was detected with a
biotinylated anti-IFN- antibody (Ab), followed by development with an
alkaline phosphatase substrate solution (5-bromo-4-chloro-3-indolyl-
phosphate [BCIP]–nitroblue tetrazolium [NBT]-plus). All samples were
tested in duplicate, and spots were counted using an automated plate
counter.
Tetramer labeling. PBMCs or T cell lines were labeled with an allo-
phycocyanin (APC)-conjugated HLA-Cw*06-CRAKFKQLL tetramer
(National Institutes of Health Tetramer Core Facility, Emory University,
Atlanta, GA) by incubation for 30min at 4°C. Cells were then washed and
incubated with Cy5.5-peridinin chlorophyll protein(PerCP)-conjugated
anti-human CD8 MAb (BioLegend, San Diego, CA), Cy7-phycoerythrin
(PE)-conjugated anti-human CD3 MAb (eBioscience, San Diego, CA),
and Alexa Fluor 700-conjugated anti-human CD4 (BD PharMingen, San
Diego, CA) for 30 min at 4°C. Cells were washed and analyzed on a BD
LSR Fortessa flow cytometer using the FACSDiva software program (BD
Biosciences).
Intracellular cytokine staining. EBV-specific T cell lines raised by in
vitro stimulation with an irradiated autologous LCL were incubated in
R10 containing various stimuli for 4 h at 37°C in the presence of 5 g/ml
brefeldin A (BioLegend). T cell lines were stimulated with either peptide-
pulsed (incubation with 1 g/ml peptide for 1 h) HLA-deficient T2 cell
lines stably transfected to express HLA-A3, A24, or B7 or serially diluted
peptide (0.0001 to 10g/ml). The cells were thenwashed and incubated at
4°C for 30 min with Live/Dead fixable aqua dead cell stain (Life Technol-
ogies, Grand Island, NY) and fluorescently labeled MAb specific for cell
surface markers (CD4-fluorescein isothiocyanate [FITC] [BD PharMin-
gen]; CD8-Cy5.5-PerCP [BioLegend]). Cells were washed and then fixed
and permeabilized with Cytofix/Cytoperm fixation/permeabilization so-
lution (BD PharMingen) at 4°C for 20 min. Next, the cells were washed
with Perm/Wash buffer (BD PharMingen), incubated with IFN-–APC
MAb (BD PharMingen) at 4°C for 30 min, and then washed again with
Perm/Wash. Cells were resuspended in phosphate-buffered saline (PBS)
for analysis on a BD FACSCanto II flow cytometer (BD Biosciences).
RESULTS
BZLF1 is a rich source of CD8 T cell epitopes. IFN- ELISpot
assays were used to screen overlapping 20-aa peptides corre-
TABLE 1 Class I HLA types of donors used in this study
Donor IDa
Allele(s)
HLA-A HLA-B HLA-C
B2 1, 11 40, 52 3, 12
B4 26, 32 40, 4402 1, 3
B5 11, 24 62, 35 3, 4
B8 2, 66 4402, 49 7, 7
B9 1, 30 8, 18 5, 7
B15 1, 26 62, 27 1, 3
B21 32, 68 7, 14 7, 8
B25 1, 2 35, 51 4, 14
B26 2, 11 35, 58 4, 7
JC33 3, 25 18, 4403 Unknown
MW65 1, 3 8, 3501 4
DP55 2 62, 18 1, 5
CG59 2, 3 7, 18 7, 12
B33 24, 29 1801, 4403 5, 16
LC50 1 8, 18 7
MR67 2 62, 57 3, 6
SB60 2 35, 57 4, 6
HB49 3, 32 7, 8 7
B7 2, 3 7, 37 6, 7
B13 1, 2 27, 57 2, 6
B22 3, 23 41, 47 6, 17
AO83 2, 24 18, 44 5, 7
KK68 1, 29 8, 4403 7, 16
B28 2, 23 4402, 53 5, 6
B38 2, 3 7, 57 6, 7
B3 1, 3 8, 40 2, 7
B10 11, 31 7, 51 7, 15
B11 11, 24 62, 50 4, 6
B14 2, 11 51 15, 16
B16 2, 11 62, 44 3, 5
B17 1, 2 7, 8 7
B19 1, 3 8, 4403 4, 7
B20 3, 24 7 7
B21 32, 68 7, 14 7, 8
B23 3, 11 35, 4402 3, 5
B24 2 40 3
a Donor identification.
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FIG 1 Initial screening of T cells from EBV-seropositive individuals against overlapping peptides spanning the BZLF1 antigen. EBV-specific T cell lines from 36
individuals, raised by in vitro stimulation with irradiated autologous LCLs, were tested by IFN- ELISpot assays for recognition of overlapping peptides (10
g/ml) corresponding to the lytic EBV BZLF1 antigen.
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sponding to the BZLF1 protein sequence for recognition by T cell
lines. These T cells were raised by in vitro stimulation of PBMCs
from 36 healthy EBV-seropositive individuals with their autolo-
gous LCLs (Table 1). Results for all individuals screened with this
overlapping peptide set are shown in Fig. 1A to C. Confirming the
importance of this small antigen as a target for T cell recognition,
only 8% (3/36) of screened individuals showed no response to any
of the BZLF1 overlapping peptides. It is notable that these three
individuals also showed no responses to overlapping peptides
from several other EBV antigens that were screened alongside the
BZLF1 peptides (data not shown), so this may reflect a general
weakness in the EBV-specific T cell response in these three donors.
It is also clear that the T cell response was biased toward restricted
regions of this antigen, with a strong focus on residues 160 to 220.
We next aimed to map the epitopes more precisely within
the BZLF1 20-mer sequences. Several individuals responded to
the overlapping peptides 56LPQGQLTAYHVSTAPTGSWF75 and
61LTAYHVSTAPTGSWFSAPQP80, and so smaller peptides from
the overlapping region were tested for recognition by T cell lines
from three of these donors. Figure 2A to C shows results from
donors B4 (HLA-A26, A32, B40, B4402, Cw1, Cw3), B5 (HLA-
A11, A24, B62, B35, Cw3, Cw4) and JC33 (HLA-A3, A25, B18,
B44). Since the pattern of recognition was quite distinct be-
tween B4/B5 and JC33, it appeared that more than one epitope
was localized in this region. Subsequent peptide dose-response
IFN- ELISpot assays (Fig. 2D and E) confirmed the presence
of two overlapping epitopes. The data indicate that the mini-
mal sequence recognized by donor B4 was the 67STAPTG-
SWF75 nonamer peptide. This novel epitope conforms to the
binding motif of HLA-Cw3, an HLA allele shared by donors B4
and B5 (Fig. 2D) (15). However, we cannot rule out the possi-
bility that the 66VSTAPTGSWF75 sequence is also an epitope for
this donor, because the dose-response curves for these two sequences
are very similar. In contrast, T cells fromdonor JC33most efficiently
recognized the overlapping 65HVSTAPTGSW74 decamer, which
conforms to theHLA-A25bindingmotif (Fig. 2E) (16). Interestingly,
Abbott et al. recently published data mapping an epitope to the
66VSTAPTGSWF75 sequence, with an ascribed HLA restriction of
HLA-B*58:01 (17); however, it is notable that the responding donor
in this study was also HLA-Cw3.
Subtle differences in the recognition of the overlapping 20-
mers corresponding to the extreme N terminus of BZLF1 were
FIG 2 Overlapping length-variant epitopes mapped from the BZLF1 antigen
of EBV. (A to C) EBV-specific T cell lines from three individuals, raised by in
vitro stimulation with irradiated autologous LCLs, were tested in IFN-
ELISpot assays for recognition of overlapping peptides (1g/ml) correspond-
ing to a region of the BZLF1 protein sequence. (D and E) EBV-specific T cell
lines from donor B4 (D) or donor JC33 (E), tested with IFN- ELISpot assays
to precisely map the minimal epitopes. Cells were tested with various concen-
trations of the indicated peptides. The experiments described for Fig. 2C, D,
and E were each performed with one other donor expressing the relevant HLA
allele, with similar results.
FIG 3 Identification of overlapping minimal epitopes from the BZLF1 anti-
gen of EBV. EBV-specific T cell lines were screened with various concentra-
tions of the indicated peptides by IFN- ELISpot assays. Results shown are
from donor B25 (A) or donor B2 (B). These experiments were each performed
with one other donor expressing the relevant HLA allele, with similar results.
Rist et al.
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also noted between donors B2 and B25. While donor B2 showed
strong responses toward peptides 11 to 30 and 16 to 35, donor B25
responded to peptides 6 to 25 and 11 to 30 (Fig. 1A). To investigate
the basis for these differences, truncated versions of these peptides
were assessed for T cell recognition, and distinct epitopes were
mapped for each donor. As shown in Fig. 3A, 14TPDPYQVPFV23
is a strongly recognized target epitope for T cells from donor B25,
with a likely HLA restriction of HLA-B51 based on the published
peptide bindingmotif for this HLAmolecule (18). In contrast, the
overlapping 18YQVPFVQAF26 nonamer is the more potent target
epitope for donor B2, with HLA-Cw4 the likely restricting mole-
cule due to its preference for binding peptides with the primary
anchor residue Phe at theC terminus (Fig. 3B) (15).With a total of
six epitopes mapped to the first 75 amino acids of the BZLF1
protein (Table 2), this N-terminal region is clearly an important
target for the T cell response.
T cell recognition for some donors was also focused on a cen-
tral region of the antigen, between residues 106 and 130 (Fig. 1). T
cells from donors MR67 and DP55 were found to recognize the
nonamer 122VQTAAAVVF130 (Fig. 4A and B), which conforms to
the binding motif of HLA-B62 (24), an allele shared by both do-
nors. This epitope encompasses another T cell determinant, rec-
ognized by donor B26: an octamer (123QTAAAVVF130) which
conforms to the HLA-B58 binding motif (25) (Fig. 4C). Abbott
and colleagues noted that the decamer 121TVQTAAAVVF130 stim-
ulated T cell responses in an HLA-B62 individual, supporting
our conclusion that this region of BZLF1 includes an HLA-B62-
restricted epitope (17).
“Hot spot” of T cell epitopes between residues 161 to 225 of
BZLF1. In 1995, Bogedain et al. first described the highly im-
munogenic HLA-B8-restricted 190RAKFKQLL197 epitope and,
in the same study, an HLA-Cw6-restricted response was local-
ized within the sequence 187RKCRAKFKQLLQHYR201 (22).
Our results confirm the presence of an HLA-Cw6-restricted
response in this region of BZLF1 and demonstrate the minimal
sequence to be 189CRAKFKQLL197, which encompasses the
HLA-B8-binding octamer epitope (Fig. 5A and C). T cell lines from
three HLA-Cw6 and HLA-B8 donors demonstrated IFN- re-
sponses to almost all overlappingpeptides that included thenonamer
189CRAKFKQLL197 (Fig. 5A). In addition, flow cytometric analysis
using the APC-conjugated HLA-Cw*06-CRAKFKQLL tetramer
confirmed that HLA-Cw6 PBMCs and EBV-specific T cell lines in-
cluded significant populations of cells that recognized the novel no-
namer peptide (Fig. 5C).
An additional epitope from BZLF1 that overlaps with 190RAK
FKQLL197 and 189CRAKFKQLL197 was discovered from a donor
who was negative for both HLA-B8 and Cw6. The results from
donor B20 show that all overlapping peptides that included the
nonamer 188KCRAKFKQL196 stimulated T cell IFN- production
(Fig. 5B). Since this sequence did not conform to the peptide
bindingmotif of any of the HLA alleles expressed by this donor,
TABLE 2 BZLF1 CD8 T cell epitopes
Epitope
coordinates (aa) Epitope sequence
Likely HLA
restriction Reference
14–23 TPDPYQVPFV B51 New data
18–26 YQVPFVQAF Cw3 New data
52–64 LPEPLPQGQLTAY B35.08 13
54–64 EPLPQGQLTAY B35.01 19
65–74 HVSTAPTGSW A25 New data
67–75 STAPTGSWF Cw3 New data
77–86 APQPAPENAY B35.08 20
79–89 QPAPENAYQAY B35.01/08 21
122–130 VQTAAAVVF B62(15.01) New data
123–130 QTAAAVVF B58 New data
169–180 EECDSELEIKRY B44.03 14
173–180 SELEIKRY B18.01 14
179–187 RYKNRVASR A31 New data
188–196 KCRAKFKQL B7 New data
189–197 CRAKFKQLL Cw6 New data
190–197 RAKFKQLL B8 22
192–200 KFKQLLQHY A30 New data
196–205 LQHYREVAA Cw8 11
209–217 SENDRLRLL B60 23
209–217 SENDRLRLL B49 New data
FIG 4 Mapping of minimal epitopes from the central region of the BZLF1
protein. IFN-ELISpot assays were used to defineminimal epitopes by screen-
ing EBV-specific T cell lines from HLA-B62 individuals, donor MR67 (A)
and donor DP55 (B), against truncated peptides at 1 g/ml and a T cell line
from the HLA-B58 individual, donor B26 (C), against various concentra-
tions of the indicated peptides. The experiment described for panel C was
performed with one other donor expressing the relevant HLA allele, with sim-
ilar results.
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we utilized the HLA-deficient T2 cell line, which was trans-
fected to express either HLA-A3, A24, or B7 as peptide-pre-
senting cells in order to determine the HLA restriction of this
response. Intracellular cytokine staining showed that a T cell
line from donor B20, which was raised by in vitro stimulation
with an autologous LCL, recognized the 188KCRAKFKQL196
peptide when presented by T2-HLA-B7 but not other antigen-
presenting cells (Fig. 5D).
Since these three epitopes differed by just one or two amino acids,
experiments were conducted to assess if T cells have the capacity to
cross-react between them or if the responses are distinct and peptide
specific. As shown in Fig. 6A to C, EBV-specific T cell populations
from individuals expressing eitherHLA-B8, Cw6, or B7were specific
for 190RAKFKQLL197, 189CRAKFKQLL197, or 188KCRAKFKQL196,
respectively, although the HLA-B8 T cells also recognized
189CRAKFKQLL197 at relatively high concentrations (Fig. 6A). These
data indicate that distinct T cell receptor repertoires are utilized
against each peptide-HLA complex.
The Gln residue at position 195 of BZLF1 is mutated to a
chargedHis residue in type 2 EBV strains and the dominant type 1
EBV strains in China. To investigate the impact of this sequence
polymorphism on the HLA-Cw6-restricted response, T cells from
donorMR67were tested for recognitionof various concentrations of
the 189CRAKFKQLL197 epitope versus the 189CRAKFKHLL197 vari-
ant (thevariant residue isunderlined).As showninFig.6D, this single
amino acid polymorphism had a significant impact on T cell recog-
FIG5 Overlapping epitopes in the coiled-coil dimerization domain of the BZLF1 EBV antigen. (A andB) EBV-specific T cells from threeHLA-Cw6 individuals
(A) and anHLA-B7 individual (B) were tested in IFN- ELISpot assays against overlapping peptides (1g/ml) corresponding to a region of the BZLF1 protein
sequence. (C) PBMCs and EBV-specific T cell lines from HLA-Cw6 individuals were analyzed by flow cytometry with the HLA-Cw6-CRAKFKQLL tetramer.
(D) HLA-deficient T2 cell lines transfected to express either HLA-A3, A24, or B7 were presensitized with the 188KCRAKFKQL196 peptide (0.1 g/ml) or left
uncoated and then washed and exposed to EBV-specific T cells from donor B20. After incubation, these T cells were analyzed for IFN- production by
intracellular cytokine staining.
Rist et al.
708 jvi.asm.org January 2015 Volume 89 Number 1Journal of Virology
 o
n
 M
ay 21, 2015 by UQ Library
http://jvi.asm.org/
D
ow
nloaded from
 
nition,withapproximately10-fold-higher concentrationsof thevari-
ant peptide required for equivalent T cell recognition.
The intense immunogenicity of this small region of BZLF1 was
further highlighted by the mapping of a fourth epitope overlap-
pingwith these threeT cell determinants. Cells from theHLA-B8
donor B9 responded not only to the 190RAKFKQLL197 epitope
(data not shown) but also to a distinct overlapping determinant
further toward the proteinC terminus. Figure 7 displays data from
donor B9, screened for T cell recognition of 8-, 9-, 10-, and 11-aa
peptides from this region. The best-recognized peptides in the
initial screen (FKQLLQHYR, QLLQHYREV, and KFKQLLQHY)
were further examined by peptide titration ELISpot assays, con-
firming the nonamer 192KFKQLLQHY200 as the minimal epitope,
with a likely restriction of HLA-A30 based on the published pep-
tide binding motif for this HLA molecule (26).
The final epitope to be mapped was from the only HLA-A31
donor included in the study. Donor B10 responded to this region
of BZLF1 (peptides 171 to 190 and 176 to 195) (Fig. 1), and the
target epitope was mapped to the nonamer 179RYKNRVASR187.
This epitope is likely to be presented by HLA-A31 based on the
publishedmotif, which has an Arg primary anchor at the C termi-
nus and Tyr and Val as secondary anchors at the second and sixth
residues, respectively (Fig. 7C) (27). This epitope lies directly ad-
jacent to the 188KCRAKFKQL196 epitope, confirming the intense
focusing of CD8 T cell epitopes in this C-terminal region of
BZLF1.
DISCUSSION
The BZLF1 antigen of EBV is an essential component of the viral
life cycle, since it plays an indispensable part in the switch from
latent to lytic gene expression. The present study explored the T
cell response to this protein by testing a large cohort of individuals
against an overlapping peptide library covering the entire antigen
and using T cell lines raised against autologous LCLs to optimize
the sensitivity of the ELISpot assays. Our data provide an extensive
list of novel epitopes within this antigen, with evidence of epitope
clustering and responses restricted through a large number of
HLA alleles (Fig. 8).
BZLF1 is clearly an important target for the T cell response to
EBV and should therefore be considered in epitope-based vaccine
strategies. Of the nine previously defined BZLF1 CD8 T cell
epitopes (Table 2), restriction was limited to seven HLA alleles,
including bothHLA-B and -C alleles but notHLA-A alleles. In this
study, we have defined a further 11 BZLF1 epitopes (Table 2),
FIG 6 T cell recognition of the clustered overlapping epitopes between residues 188 and 197. EBV-specific T cell populations from individuals expressing either
HLA-B8 (A), Cw6 (B), or B7 (C) were tested for recognition of the peptides 190RAKFKQLL197, 189CRAKFKQLL197, and 188KCRAKFKQL196 at various concen-
trations by intracellular cytokine staining. (D)T cells from theHLA-Cw6 donorMR67were also tested in an ELISpot assay for recognition of the variant peptide
189CRAKFKHLL197 (the variant residue is underlined), in comparison to the results with 189CRAKFKQLL197 epitope.
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including epitopes restricted through HLA-A as well as HLA-B
and -C alleles, thereby significantly increasing the population cov-
erage. Indeed, 8 out of the 36 individuals tested in this study
showed responses directed toward these novel epitopes but not
previously defined epitopes.
Woodberry and colleagues showed that BZLF1 responses are
significant in acute infectious mononucleosis, as well as during
persistent EBV infection (28). Considering that the BZLF1 protein
is only 245 aa in length, it is notable that almost half of these amino
acids (105, or 42.9%) are included in epitopes. The transactivation
domain (1 to 166) includes 10 epitopes, six of which were defined
in this study. Furthermore, in a region of just 37 aa between resi-
dues 169 and 205, up to eight epitopes are present. This region
includes theDNA recognition domain (178 to 194) and part of the
coiled-coil dimerization domain. Located within the coiled-coil
dimerization domain is the previously mapped HLA-B60-re-
stricted nonamer epitope 209SENDRLRLL217 (23). Interestingly,
we have also found an HLA-B60-negative individual whose cells
responded to this epitope (data not shown). Cells from this indi-
vidual (donor B8; HLA-A2, A66, B4402, B49, Cw7) expressed
HLA-B49, which is likely to be the restricting allele based on the
bindingmotif of HLA-B49, which includes anchor residues Glu at
position 2 and Leu at the C terminus. It is notable that McDonald
and colleagues found the motif 209SENDRLR215, located midway
along the coiled-coil dimerization region, to play a key role in the
BZLF1 structure and to be required for EBV DNA replication
(29). In addition, the leucine at residue 217 is suggested to be
important for dimerization, since it is positioned adjacent to the
interacting faces of the helices (10). This presumably explains why
this sequence and the nonamer epitope are conserved in both type
1 and 2 EBV strains.
Why are some regions of the BZLF1 sequence so rich in CD8
T cell epitopes while other areas are not targeted at all? One pos-
sibility is that sequence similarity with human protein sequences
results in immune tolerance to parts of the BZLF1 antigen. Several
previous studies have shown the phenomenon of epitope cluster-
ing. Examples range from bacteria and tumor antigens to HIV.
Kim and DeMars found that the major outer membrane protein
of Chlamydia trachomatis displays a coclustering of class I and
class II epitopes within a 20-mer region of the protein (30). Fur-
thermore, Valmori and colleagues identified clusters of closely
overlapping epitopes in the NY-ESO-1 protein (expressed in sev-
eral types of tumors) (31). HIV studies have shown epitope clus-
tering in the Nef and Gag proteins, corresponding to areas of
protein hydrophobicity. Interestingly, CD8 T cell epitopes are
predicted to be quite evenly distributed throughout the BZLF1
sequence according to the Immune Epitope Analysis Resource
(http://tools.immuneepitope.org/main/) for 10 common HLA
class I alleles (data not shown), which uses predictors of protea-
somal processing, TAP transport, and MHC binding to produce
an overall score for each peptide’s intrinsic potential for being a T
cell epitope.
HLA polymorphism has evolved to ensure that a wide range of
antigenic epitopes are presented across the population in order to
reduce the impact of amino acid mutation within T cell epitopes.
The clustering of epitopes and the sharing of amino acids between
multiple epitopes has the potentially dangerous consequence that
viral escape mutants may impact on a large proportion of the
population. An example of this is theGln residue at position 195 of
BZLF1, which is included within four epitopes restricted by either
HLA-A30, -B7, -B8, or -Cw6. Importantly, the Gln residue is mu-
tated to a charged His residue in type 2 EBV strains and the dom-
inant type 1 EBV strains in China (32). Since HLA-Cw6 is ex-
pressed at a high frequency in parts of China, we examined the
impact of this sequence polymorphism on recognition by HLA-
Cw6-restricted T cells raised against the 189CRAKFKQLL197
epitope. T cell recognition was significantly reduced by the Q195-
to-H195 variation, raising the interesting possibility that this vari-
ant may have arisen in the Chinese population as an escape mu-
tant.
FIG 7 Identification of two HLA-A-restricted epitopes in the BZLF1 EBV
antigen. (A) EBV-specific T cells from the HLA-A30 individual, donor B9,
were tested by IFN- ELISpot assays against overlapping peptides (1 g/ml)
corresponding to a region of the BZLF1 antigen. (B) Subsequent IFN-
ELISpot assays mapped the minimal epitope by screening the indicated pep-
tides at various concentrations. (C) EBV-specific T cells from the HLA-A31
individual, donor B10, were tested by IFN- ELISpot assays with overlapping
peptides (1 g/ml) as shown. The experiment described for panel A was per-
formed with one other donor expressing the relevant HLA allele, with similar
results.
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Our work adds significantly to the understanding of the im-
mune response to BZLF1, the most highly immunogenic T cell
target antigen from EBV. Precisely mapped T cell epitopes have
become a critical tool for analyzing the immune response to
pathogens through, for example, HLA-peptide multimers. Fur-
thermore, they are also being used directly in vaccine development
and adoptive immunotherapy, particularly for tumor-associated
viruses, such as EBV, from which individual proteins are poten-
tially oncogenic (33). We have greatly expanded the number of
defined CD8 T cell epitopes from BZLF1 and highlighted their
clustered distribution along the length of the sequence. This in-
formation is likely to be widely utilized in future studies aimed at
manipulating the immune system to treat or prevent EBV-associ-
ated diseases.
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